Biotage AB
STO:BIOT

Watchlist Manager
Biotage AB Logo
Biotage AB
STO:BIOT
Watchlist
Price: 160.7 SEK 0.63% Market Closed
Market Cap: 12.9B SEK
Have any thoughts about
Biotage AB?
Write Note

Biotage AB
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biotage AB
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Biotage AB
STO:BIOT
Other Current Liabilities
kr546m
CAGR 3-Years
37%
CAGR 5-Years
89%
CAGR 10-Years
52%
AddLife AB
STO:ALIF B
Other Current Liabilities
kr490m
CAGR 3-Years
14%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Other Current Liabilities
kr378.6m
CAGR 3-Years
120%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genovis AB
STO:GENO
Other Current Liabilities
kr16.3m
CAGR 3-Years
7%
CAGR 5-Years
9%
CAGR 10-Years
11%
MedCap AB (publ)
STO:MCAP
Other Current Liabilities
kr41.9m
CAGR 3-Years
41%
CAGR 5-Years
30%
CAGR 10-Years
16%
M
Magle Chemoswed Holding AB
STO:MAGLE
Other Current Liabilities
kr13.5m
CAGR 3-Years
12%
CAGR 5-Years
-29%
CAGR 10-Years
N/A
No Stocks Found

Biotage AB
Glance View

Market Cap
12.9B SEK
Industry
Life Sciences Tools & Services

Biotage AB, a Swedish life sciences company, has carved a significant niche within the analytical and organic chemistry sectors since its inception. The company's core operations revolve around the development of innovative solutions designed to facilitate drug discovery, genetic research, and infection diagnostics. By offering products that simplify and accelerate chemical synthesis, Biotage has become essential to the pharmaceutical and biotechnology industries. The company's product lineup includes automated sample preparation systems, flash chromatography instruments, and peptide synthesis solutions. These tools are indispensable for researchers and lab technicians, making complex laboratory processes more efficient and less time-consuming. Financially, Biotage generates revenue through the sale and distribution of its cutting-edge laboratory instruments and their accompanying consumables. In addition to equipment sales, the company also engages in service contracts and after-sales support, which provides a steady stream of recurring income. This dual model of one-time equipment purchases combined with ongoing service and supply needs ensures a stable revenue base. Biotage stays competitive by continually innovating and refining its technology, ensuring its solutions remain indispensable to scientists addressing critical challenges in medicine, environmental testing, and other fields that demand highly precise chemical processes.

BIOT Intrinsic Value
181.41 SEK
Undervaluation 11%
Intrinsic Value
Price

See Also

What is Biotage AB's Other Current Liabilities?
Other Current Liabilities
546m SEK

Based on the financial report for Sep 30, 2024, Biotage AB's Other Current Liabilities amounts to 546m SEK.

What is Biotage AB's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
52%

Over the last year, the Other Current Liabilities growth was 4%. The average annual Other Current Liabilities growth rates for Biotage AB have been 37% over the past three years , 89% over the past five years , and 52% over the past ten years .

Back to Top